Tumor-suppressive effects of atelocollagen-conjugated hsa-miR-520d-5p on un-differentiated cancer cells in a mouse xenograft model

Ishihara, Y.; Tsuno, Satoshi; Kuwamoto, Satoshi; Yamashita, Taro; Endo, Yusuke; Miura, Keigo; Miura, Yugo; Sato, Takemasa; Hasegawa, Junichi; Miura, Naruhisa

doi:10.1186/s12885-016-2467-y

Cited by 7 publications

(8 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Viral platforms have been found to be insufficient due to triggering of immune response [ 221 ]. Non-viral vectors include: inorganic miRNA platforms (e.g., Fe 3 O 4 -based nanoparticles [ 222 ], gold or nanodiamonds platforms [ 223 ], and silica-based systems [ 224 ]), polymer-based miRNA delivery systems (such as polyamidoamine dendrimers—PAMAMs [ 225 , 226 ], or atelocollagen [ 227 , 228 ]) and lipid-based platforms [ 229 , 230 ].…”

Section: Applications Of Transcriptome Analysis In Oncologymentioning

confidence: 99%

Current Achievements and Applications of Transcriptomics in Personalized Cancer Medicine

Supplitt

Karpiński

Sasiadek

et al. 2021

IJMS

View full text Add to dashboard Cite

Over the last decades, transcriptome profiling emerged as one of the most powerful approaches in oncology, providing prognostic and predictive utility for cancer management. The development of novel technologies, such as revolutionary next-generation sequencing, enables the identification of cancer biomarkers, gene signatures, and their aberrant expression affecting oncogenesis, as well as the discovery of molecular targets for anticancer therapies. Transcriptomics contribute to a change in the holistic understanding of cancer, from histopathological and organic to molecular classifications, opening a more personalized perspective for tumor diagnostics and therapy. The further advancement on transcriptome profiling may allow standardization and cost reduction of its analysis, which will be the next step for transcriptomics to become a canon of contemporary cancer medicine.

show abstract

Section: Applications Of Transcriptome Analysis In Oncologymentioning

confidence: 99%

Current Achievements and Applications of Transcriptomics in Personalized Cancer Medicine

Supplitt

Karpiński

Sasiadek

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Therefore, the zebrafish was also shown to be a successful model system for assessing tumor response to anticancer therapy in vivo . In summary, despite the fact that the zebrafish is a simple model system, the striking properties of D. rerio permit the use of this organism to better understand the effects of aberrant changes in endogenous levels of certain miRNAs (21,22). The zebrafish has been proven to be a successful model system, leading to the recognition of several miRNAs through basic biochemical and molecular studies, and has great potential as a model to identify clinically relevant miRNAs.…”

Section: Mirnamentioning

confidence: 99%

Role of non‑coding RNA in pancreatic cancer (Review)

Huang

2019

Oncol Lett

View full text Add to dashboard Cite

Pancreatic cancer is a malignant disease that develops rapidly and carries a poor prognosis. Currently, surgery is the only radical treatment. Non-coding RNAs (ncRNAs) are protein-free RNAs produced by genome transcription; they play important roles in regulating gene expression, participating in epigenetic modification, cell proliferation, differentiation and reproduction. ncRNAs also play key roles in the development of cancer; microRNA (miRNA) and long non-coding RNA (lncRNA) may lead the way to new treatments for pancreatic cancer. miRNAs are short-chain ncRNAs (19-24 nt) that inhibit the degradation of protein translation or their target gene mRNAs to regulate gene expression. lncRNAs contain >200 nt of ncRNA and play important regulatory roles in a number of malignant tumors, in terms of tumor cell proliferation, apoptosis, invasion and distant metastasis. lncRNAs can be exploited for the diagnosis and treatment of pancreatic cancer and have substantial prospects for clinical application. Nevertheless, the molecular mechanism of their regulation and function, as well as the significance of other ncRNAs, such as piwi-interacting RNA, in the pathogenesis of pancreatic cancer, are largely unknown. In this review, the structures of ncRNAs with various classifications, as well as the functions and important roles of ncRNAs in the diagnosis and treatment of pancreatic cancer are reviewed.

show abstract

“…In the case of miR-520d-5p that can convert undifferentiated hepatoma cells to benign or normal status in vivo [27], there are more than 1,000 predicted target genes, according to available bioinformatics. Because the effect of miR-520d-5p on not only cancer cells but also normal cells clarified no toxicity and no tumorigenicity in vivo studies [28,29], we, hereby, examined anticancer effects including the therapeutic effects of 520d-5p conjugated with an atelocollagen as a DDS carrier on three differentiated types of PC cell lines, by in vivo studies.…”

Section: Gene Expression Analysis By Reverse Transcription-polymerase Chain Reaction (Rt-pcr)mentioning

confidence: 99%

A novel anti-cancer effect of atelocollagen-conjugated miR-520d-5p on pancreatic cancer cells in vitro and in a mouse xenograft model

Ishihara¹,

Miura²,

Miura³

et al. 2019

Integr Mol Med

Self Cite

View full text Add to dashboard Cite

Background:We have previously shown that hsa-miR-520d-5p can convert undifferentiated hepatoma cells into the status of pluripotent stem cells or mesenchymal stem cells (MSCs) via a demethylation process and P53 upregulation in vivo. Here, we examined anti-cancer effect of miR-520d-5p on three human pancreatic cancer (PC) cells. Material and methods:After generating GFP-expressing cancer cells, we transfected 520d-5p into three PC cell lines (KLM-1, PK-45p or PK-9) to examine the key gene expression and the change of malignant properties. Also, we examined the therapeutic effect of 520d-5p on KLM-1 using atelocollagen-conjugated miR-520d-5p (520d/atelocollagen).Results: Tumor growth was suppressed by more than 80% each week by 520d/atelocollagen, compared with scramble/atelocollagen (scram./.atelocollagen) or atelocollagen alone. Interestingly, 520d-5p induced PK-9 cells to the transformation accompanied by apoptosis, resulting in the benignant transformation like pancreatic acinar cells with the functions of secreting pancreatic enzyme (lipase or amylase) without malignant properties.Conclusions: This is the first reports that we confirmed an anti-cancer effect of 520d/atelocollagen or the benignant conversion on PC cells in vivo study. The development to optimize this carrier for drug delivery system (DDS) is expected to elevate the efficiency to enter each tumor cell and provide for the miRNA medicine as a novel therapeutic modality.

show abstract

Tumor-suppressive effects of atelocollagen-conjugated hsa-miR-520d-5p on un-differentiated cancer cells in a mouse xenograft model

Cited by 7 publications

References 48 publications

Current Achievements and Applications of Transcriptomics in Personalized Cancer Medicine

Current Achievements and Applications of Transcriptomics in Personalized Cancer Medicine

Role of non‑coding RNA in pancreatic cancer (Review)

A novel anti-cancer effect of atelocollagen-conjugated miR-520d-5p on pancreatic cancer cells in vitro and in a mouse xenograft model

Contact Info

Product

Resources

About